6CM
MSLE

683 Capital Management’s Satellos Bioscience MSLE Stock Holding History

683 Capital Management’s Portfolio MSLE Stock Details MSLE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.79M Hold
230,833
– – 0.09% 109
2026
Q1 		$1.3M Buy
+230,833
New +$2.27M 0.07% 130

Other funds holding MSLE

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

683 Capital Management's MSLE Position: Q2 2026 in Review

683 Capital Management held its Satellos Bioscience (MSLE) position steady in Q2 2026 at 230,833 shares worth $1.79M. The position accounts for 0.09% of the portfolio, ranked #109.

683 Capital Management first reported a position in MSLE in Q1 2026 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold MSLE as of Q2 2026.

  • 683 Capital Management held 230,833 shares of Satellos Bioscience worth $1.79M as of Q2 2026.
  • 683 Capital Management left its Satellos Bioscience share count unchanged in Q2 2026.
  • Satellos Bioscience made up 0.09% of 683 Capital Management's portfolio in Q2 2026, its #109 holding.
  • 683 Capital Management first reported a position in Satellos Bioscience in Q1 2026 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held Satellos Bioscience as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.